Detail akcie HOOKIPA Pharma Rg online

Business Summary: HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Hookipa Pharma Inc revenues decreased 95% to $2M. Net loss totaled $15.4M vs. income of $14.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects General and administrative - Balancing v increase of 73% to $7.2M (expense), R&D Expense - Government Grants decrease of 90% to $227K (income).